AKT1 and Epstein-Barr virus infection: To confirm the role of RTK signalling pathways in EBV infection, EGF-treated HNE1 and NPEC1-Bmi1 cells pre-incubated with inhibitors of tyrosine kinases (Genistein), MEK1/MEK2 (U0126), PI3K/AKT (LY294002), EGFR (Gefitinib) and VEGFR2/PDGFR/Raf signalling cascades (Sorafenib), were infected with EBV.